News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now
Press Release
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now
News
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
Press Release
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
News
This Scientist Is Building Custom Gene-Editing Tools
July 25, 2023
Forbes
Read Now
Press Release
This Scientist Is Building Custom Gene-Editing Tools
July 25, 2023
Forbes
Read Now
News
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now
Press Release
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now